Noah Puleo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Noah Puleo has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Analisa DiFeo
Department of Pathology, University of Michigan, Ann Arbor, USA
122 shared publications - Michele L. Dziubinski
Department of Pathology, University of Michigan, Ann Arbor, Michigan
103 shared publications - Alexander M. Sobeck
University of Michigan 1 Department of Pathology Ann Arbor, Michigan
100 shared publications - Dafydd Thomas
Department of Pathology, University of Michigan, Ann Arbor, Michigan
100 shared publications - Jose A. Colina
University of Michigan 1 Department of Pathology Ann Arbor, Michigan
100 shared publications - Rita A. Avelar
University of Michigan 1 Department of Pathology Ann Arbor, Michigan
100 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S2: Validation of NCB-0846 in selectively targeting platinum-resistant HGSC across cell models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S2: Validation of NCB-0846 in selectively targeting platinum-resistant HGSC across cell models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Table S1: Compounds from the BenevolentAI library created for screening in spheroid grown OV81-CP40 and OV231-CP30 cells. Results reported as mean fold change cell viability relative to DMSO control with standard deviation; n = 4.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Table S1: Compounds from the BenevolentAI library created for screening in spheroid grown OV81-CP40 and OV231-CP30 cells. Results reported as mean fold change cell viability relative to DMSO control with standard deviation; n = 4.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S4: Densitometry for Figure 4 western blots
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S4: Densitometry for Figure 4 western blots
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S3: Validation of lithium chloride and Figure 3 western blot densitometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S3: Validation of lithium chloride and Figure 3 western blot densitometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S6: Inhibition of MYC is important in TNIK and CDK9-mediated targeting efficacy as observed through HEC1B treatment with NCB-0846
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S6: Inhibition of MYC is important in TNIK and CDK9-mediated targeting efficacy as observed through HEC1B treatment with NCB-0846
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S5: CDK9 inhibition shows platinum-resistant HGSC efficacy and specificity and mediates responses to enhanced Wnt activity.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S5: CDK9 inhibition shows platinum-resistant HGSC efficacy and specificity and mediates responses to enhanced Wnt activity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Table S3: IC50s of patient-derived organoids.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Table S3: IC50s of patient-derived organoids.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Table S2: Patient information and treatment regimen for OV-UM32.1, OV-UM50.2 and OV-UM52.1 cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Table S2: Patient information and treatment regimen for OV-UM32.1, OV-UM50.2 and OV-UM52.1 cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Table S4: Artificial intelligence predicted additional target kinases for NCB-0846.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Table S4: Artificial intelligence predicted additional target kinases for NCB-0846.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S1: Characterization of OV81-CP40 and OV231-CP30 cell lines and results of GSEA for OV81-CP40 RNAseq.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer
Supplementary Figure S1: Characterization of OV81-CP40 and OV231-CP30 cell lines and results of GSEA for OV81-CP40 RNAseq.